New patient treatment, phase 2 initiated
A patient was treated on Tuesday April 9th, 2019, in SpectraCure's clinical trial for the treatment of patients with recurrent prostate cancer, at University College London Hospital.
The treatment was performed with SpectraCure's photodynamic therapy (PDT) method. The procedure went as expected and the patient is doing well.
"It is gratifying that we are now officially entering the Phase 2 study together with our clinical partners," comments Masoud Khayyami, CEO.
The purpose of the Phase 2 study is to, with a larger statistical basis than in the Phase 1 study, show that the method is safe to use and that it has clinical effect.
For further information, please contact:
SpectraCure AB publ, CEO, Masoud Khayyami, phone: +46 (0) 70 815 21 90
Certified Adviser is G&W Fondkommission, e-mail: firstname.lastname@example.org, phone: +46(0) 8 503 000 50
This information is information that SpectraCure AB is required to disclose under the EU Market Abuse Regulation. The information was provided, through the contact of the above contact person, for publication on April 10th, 2019 10:46 a.m.
SpectraCure in short
SpectraCure was founded in 2003 as a spin off from Lund University departments for medical laser applications and physics. The company focuses on cancer treatments using medical systems with laser light sources and reactive drugs, which is referred to as "Interstitial Photodynamic Therapy", PDT, a treatment methodology suitable for internal solid tumours of various kind, e.g. prostate and abdominal salivary glands, but also other indications such as cancer tumours in the head and neck region